WHAT YOU NEED TO KNOW
- The White House withdrew Dr. Heidi Overton’s FDA nomination hours before a Senate committee vote.
- Overton faced opposition involving abortion policy, flavored vapes and distrust from parts of the MAHA movement.
- Sen. Bill Cassidy maintained that Overton had a viable path to confirmation in the committee and full Senate.
- The withdrawal could leave the FDA without a permanent leader well into next year.
The White House abruptly withdrew Dr. Heidi Overton’s nomination to lead the Food and Drug Administration late Tuesday, just hours before a Senate committee was scheduled to consider advancing her. A White House official and two other people familiar with the matter said Trump officials believed multiple Senate Republicans remained skeptical.
The decision capped weeks of mounting scrutiny from Republican senators and activists aligned with Health and Human Services Secretary Robert F. Kennedy Jr. Overton, a senior White House aide, also faced resistance from lawmakers with sharply different positions on abortion policy.
Senate committee chair Sen. Bill Cassidy insisted Overton was close to securing enough support. Shortly after the withdrawal, Cassidy wrote on X that the White House had “abandoned a viable confirmation path for Dr. Overton.”
Cassidy said he had been holding productive conversations with members and believed Overton could have passed both the committee and the full Senate. The White House did not immediately respond to his assessment.
Trump officials had recently worked to counter threats against Overton’s nomination from conservative Sen. Josh Hawley and the wider abortion opposition movement. Two people familiar with the matter said those critics were angry about the administration’s lack of urgency in restricting distribution of mifepristone.
At the same time, Sens. Susan Collins and Lisa Murkowski, both abortion rights proponents, had concerns about Overton’s strong support for policies opposing abortion. They also questioned her role in the administration’s approval of flavored vapes.
The nomination exposed friction between Kennedy’s Make America Healthy Again movement and more traditional conservative groups. As a senior domestic policy aide, Overton had served for the past year and a half as the main link between HHS leaders pursuing several MAHA policies and senior White House officials who had stalled them.
Those delays generated frustration and distrust within the broader MAHA movement. Although Kennedy praised Overton’s nomination in August, people familiar with their interactions described the relationship as distant, with one characterizing it as “not good” and another saying, “She’s not MAHA.”
Cassidy said senators opposing abortion had sought final assurances about the administration’s commitment to life issues. He added that the administration withdrew Overton instead of providing those commitments.
Overton became the latest health care nominee withdrawn as Republican support deteriorated. The White House had previously pulled nominees chosen to lead the Centers for Disease Control and Prevention and the surgeon general’s office after moderate Republicans raised concerns.
Her withdrawal is likely to leave the FDA without a permanent leader well into next year. Cassidy indicated that another nominee probably would not be considered before Republicans lose control of the Senate in January, saying confirmation would fall to Senate Democrats.
Overton had met privately the previous week with Cassidy, the outgoing Louisiana senator and physician. Two people briefed on the meeting said she and her team left confident about her prospects, and Cassidy scheduled the committee vote soon afterward without publicly endorsing her.
MORE NEWS: U.S. Officially Loses Measles Elimination Status as Virus Roars Back: Who Needs Another Shot?
Public doubts quickly returned. Cassidy told CBS’ “Face the Nation” on Sunday that he did not know whether Overton had sufficient votes, while Collins remained publicly uncommitted after questioning Overton during her confirmation hearing about flavored vapes.
Posters also appeared across Washington, DC, urging senators to reject “Heidi Vaperton” and accusing her of supporting large tobacco companies and an abortion ban. Health in Office, a nonpartisan group concerned about the administration’s health agenda, organized the posters, according to reporting first published by The Washington Post.
Calley Means, a MAHA advocate and White House senior adviser who left the administration in October, accused Overton during an interview with “The Joe Rogan Experience” of working to “relax standards on fruit flavored vapes.” He also alleged that she placed corporate interests ahead of the MAHA agenda, claims on which Overton has not publicly commented.
Former White House chief of staff Susie Wiles had provided critical support for Overton’s selection earlier in the year. After Wiles was replaced by Stephen Miller, the new chief of staff signaled stronger support for Kennedy and the MAHA coalition, which had long viewed Overton’s candidacy skeptically.
The White House offered no immediate timeline for choosing another nominee. Outgoing Kansas Sen. Roger Marshall has expressed interest in the position, while some MAHA advocates celebrated Overton’s withdrawal, including Vani Hari, who wrote on X: “Another one bites the dust.”
Join the Discussion
COMMENTS POLICY: We have no tolerance for messages of violence, racism, vulgarity, obscenity or other such discourteous behavior. Thank you for contributing to a respectful and useful online dialogue.